Low Incidence of Extrapyramidal Symptoms in Subjects with Tardive Dyskinesia Receiving Long-Term Valbenazine (NBI-98854) Treatment
Objective: To assess the emergence of extrapyramidal symptoms (EPS) such as akathisia and parkinsonism in adults with a diagnosis of schizophrenia/schizoaffective disorder or mood disorder…Prevalence of Parkinson’s disease and Drug-induced Parkinsonism from National Health Insurance Service Claims Data (NHISCD)
Objective: To evaluate the prevalence and characteristics of of drug induced parkinsonism Background: Drug induced parkinsonism (DIP) is a clinically important disease because it can…Drug-induced movement disorders: not a typical problem
Objective: To characterize patients with neuroleptic drug-induced movement disorders (DIMD) referred to a single academic center Movement Disorders clinic, their causative medications and the indications…Long-Term Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study
Objective: To evaluate the long-term safety/tolerability of deutetrabenazine (DTB) in patients with tardive dyskinesia (TD). Week 54 open-label results are reported in this interim analysis.…Effect of Deutetrabenazine on Quality of Life in Patients With Tardive Dyskinesia in AIM-TD, a 12-Week Double-Blind, Placebo-Controlled Study
Objective: To assess the effect of deutetrabenazine (DTB) on quality of life (QoL) of patients with tardive dyskinesia (TD) as measured by the modified Craniocervical…Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD and AIM-TD Studies
Objective: To evaluate the efficacy of deutetrabenazine (DTB), as measured by the Clinical Global Impression of Change (CGIC), in patients with tardive dyskinesia (TD) from…An MCID for AIMS Dyskinesia Total Score Change in Subjects with Tardive Dyskinesia
Objective: To establish a minimal clinically important difference (MCID) for Abnormal Involuntary Movement Scale (AIMS) dyskinesia total score change using data from randomized, double-blind, placebo…Deutetrabenazine Treatment Response by Concomitant Dopamine-Receptor Antagonists in the Phase III, Randomized, Double-Blind, Placebo-Controlled AIM-TD Trial in Tardive Dyskinesia
Objective: To determine the impact of dopamine-receptor antagonist (DRA) use at baseline on the efficacy, safety, and tolerability of deutetrabenazine in patients with tardive dyskinesia…Evaluation of Patient-Reported Outcomes in Tardive Dyskinesia Patients With Underlying Psychotic and Mood Disorders in the ARM-TD and AIM-TD Trials
Objective: To assess patients’ impression of treatment benefit from deutetrabenazine (DTB) for the treatment of tardive dyskinesia (TD). Background: In TD, patients’ perception of benefit…Tardive Dyskinesia by Body Region in Subjects with Schizophrenia/Schizoaffective Disorder or Mood Disorder: Findings from the KINECT 3 Study
Objective: To characterize dyskinesia distribution by body region in subjects with tardive dyskinesia (TD) enrolled in a clinical trial of valbenazine, based on baseline Abnormal…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.